- Home
- TGB vs PRAX Comparison
TGB vs PRAX Comparison
Compare TGB & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGB
- PRAX
- Stock Information
- Founded
- TGB 1966
- PRAX 2015
- Country
- TGB Canada
- PRAX United States
- Employees
- TGB N/A
- PRAX N/A
- Industry
- TGB Precious Metals
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- TGB Basic Materials
- PRAX Health Care
- Exchange
- TGB Nasdaq
- PRAX Nasdaq
- Market Cap
- TGB 1.1B
- PRAX 952.1M
- IPO Year
- TGB N/A
- PRAX 2020
- Fundamental
- Price
- TGB $3.93
- PRAX $181.63
- Analyst Decision
- TGB Hold
- PRAX Strong Buy
- Analyst Count
- TGB 1
- PRAX 11
- Target Price
- TGB $5.00
- PRAX $127.55
- AVG Volume (30 Days)
- TGB 5.6M
- PRAX 1.1M
- Earning Date
- TGB 11-05-2025
- PRAX 11-05-2025
- Dividend Yield
- TGB N/A
- PRAX N/A
- EPS Growth
- TGB N/A
- PRAX N/A
- EPS
- TGB N/A
- PRAX N/A
- Revenue
- TGB $424,271,553.00
- PRAX $7,765,000.00
- Revenue This Year
- TGB $9.68
- PRAX N/A
- Revenue Next Year
- TGB $44.23
- PRAX $20.00
- P/E Ratio
- TGB N/A
- PRAX N/A
- Revenue Growth
- TGB N/A
- PRAX 338.45
- 52 Week Low
- TGB $1.67
- PRAX $26.70
- 52 Week High
- TGB $4.84
- PRAX $205.89
- Technical
- Relative Strength Index (RSI)
- TGB 47.18
- PRAX 95.60
- Support Level
- TGB $4.35
- PRAX $50.56
- Resistance Level
- TGB $4.72
- PRAX $205.89
- Average True Range (ATR)
- TGB 0.20
- PRAX 7.97
- MACD
- TGB -0.06
- PRAX 13.38
- Stochastic Oscillator
- TGB 2.39
- PRAX 96.58
About TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.